Valuation: Keros Therapeutics, Inc.

Market Cap 199M 175M 163M 149M 280M 19.17B 285M 1.93B 754M 9.43B 747M 731M 32.59B P/E 2026 *
-1.68x
P/E 2027 * -1.84x
Enterprise Value 199M 175M 163M 149M 280M 19.17B 285M 1.93B 754M 9.43B 747M 731M 32.59B EV / Sales 2026 *
46.8x
EV / Sales 2027 * 10.5x
Free-Float
46.57%
Yield 2026 *
-
Yield 2027 * -
1 day-0.79%
1 week-5.45%
Current month-5.98%
1 month-7.88%
3 months-12.60%
6 months-47.60%
Current year-50.59%
1 week 9.92
Extreme 9.915
10.97
1 month 9.92
Extreme 9.915
12.18
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 2015-11-30
Director of Finance/CFO 56 2020-01-31
Chief Tech/Sci/R&D Officer 53 2019-05-31
Director TitleAgeSince
Chairman 70 2024-06-30
Director/Board Member 63 2016-03-31
Director/Board Member 50 2020-02-29
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Buy

Chairman

1,000 0.0051%
7/1/26 Free

Director

28,656 0.1448%
6/15/26 Buy

Chairman

1,000 0.0051%
Change 5-day change 1-year change 3-year change Capi.($)
-0.79%-5.45%-30.04%-76.61% 201M
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+6.97%+62.83%+67.97% 56.67B
-2.97%-2.35%-22.03%-16.54% 23.28B
-0.46%-1.29%+3.28%+422.58% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%-0.63%+29.60%-32.53% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
-0.50%-0.98%+23.62%+178.38% 13.99B
Average -1.02%-0.02%+34.97%+149.80% 24.22B
Weighted average by Cap. -0.89%+1.46%+42.86%+137.84%

Financials

2026 *2027 *
Net sales 4.25M 3.73M 3.47M 3.19M 5.99M 409M 6.08M 41.24M 16.11M 201M 15.96M 15.62M 696M 18.91M 16.61M 15.45M 14.17M 26.63M 1.82B 27.04M 183M 71.66M 895M 70.99M 69.46M 3.1B
Net income -120M -106M -98.39M -90.28M -170M -11.6B -172M -1.17B -456M -5.7B -452M -442M -19.72B -132M -116M -108M -98.92M -186M -12.71B -189M -1.28B -500M -6.25B -495M -485M -21.6B
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
87
Date Price Change Volume
26-07-24 US$10.06 -0.79% 140,634
26-07-23 US$10.14 -0.69% 217,402
26-07-22 US$10.21 -3.41% 180,430
26-07-21 US$10.57 -0.38% 113,320
26-07-20 US$10.61 -0.28% 199,200
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
10.06USD
Average target price
21.83USD
Spread / Average Target
+117.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock